FridayJan 24, 2020 12:44 pm

Predictive Oncology Inc. (NASDAQ: POAI) Appoints New Board Member, Audit Committee Chair

New board member, audit committee chair brings 35 years of accounting experience, mainly in management Prior worked as CFO, controller in several genomics, health companies POAI to leverage Prior’s new insights, guidance in the financial space Predictive Oncology Inc. (NASDAQ: POAI), a leader in the cancer precision-medicine field, announced that Pam Prior, CPA, has been appointed to the company's Board of Directors. In addition to holding a seat on the board, Prior will also chair the company’s audit committee. Prior, 57, joins POAI’s Board of Directors with 35 years of experience in accounting, mainly in management as CFO or controller.…

Continue Reading

FridayJan 17, 2020 12:42 pm

Predictive Oncology Inc. (NASDAQ: POAI), Leader in Precision Medicine, Committed to Playing Key Role in Decreasing Cancer Deaths

American Cancer Society annual report shows largest single-year drop in cancer deaths ever reported Doctors attribute precision medicine with playing significant role in decline POAI leading player in precision medicine, initiated groundbreaking Cancer Quest 2020 project A new American Cancer Society report bodes well for Predictive Oncology Inc. (NASDAQ: POAI), a company focused on applying artificial intelligence to help equip players in personalized medicine and drug discovery. American Cancer Society’s annual ‘Facts & Figures 2020’ report shows the largest single-year drop in cancer deaths ever reported (http://nnw.fm/twL1W). The 2.2% drop occurred from 2016 to 2017, the most recent year for…

Continue Reading

MondayJan 13, 2020 12:11 pm

Predictive Oncology Inc.’s (NASDAQ: POAI) Disruptive Platform Overcoming Obstacles in Precision Medicine Industry

The global precision medicine market is estimated to reach $84.6 billion by 2024 Predictive Oncology is bringing cutting-edge technology to cancer research to develop highly customizable assessment methods that improve patient outcomes POAI leverages unique competitive advantage that stems from readily available access to historical data on tumor profiles and their drug responses Precision medicine, an approach that seeks to understand the genetic makeup of a patient’s tumor in order to customize a drug targeting the particular gene type for each patient, offers tremendous potential for the treatment of a number of diseases. Predictive Oncology Inc. (NASDAQ: POAI), a data…

Continue Reading

FridayJan 10, 2020 1:09 pm

Predictive Oncology Inc. (NASDAQ: POAI) Working to Create World’s First Comprehensive, Actionable Multi-Omic Data Set for Ovarian Cancer

POAI plans to have first predictive model of ovarian cancer ready for initial commercialization in Q1 2020 First batch of 400 ovarian cancer subjects in initiative has been sequenced Groundbreaking AI-driven model of ovarian cancer will be capable of predicting tumor drug response, patient outcome Predictive Oncology Inc. (NASDAQ: POAI), a company focused on applying artificial intelligence to personalized medicine and drug discovery, has updated the commercialization of its pioneering CancerQuest 2020 initiative (http://nnw.fm/y6fnc). Based on the updated announcement, the company plans on having its first predictive model of ovarian cancer ready for initial commercialization in revenue-generating projects with Pharma…

Continue Reading

Official NewsWire Relationships

BIO Informa DGE Dynamic Global Events DTC Healthcare Conference Kiasco Reasearch Nexus Conferences Octane

BioMedWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 415.949.5050